AT-56
Based on 1 publication(s) in Google Scholar
AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 162640-98-4
- Formula: C25H27N5
- Molecular Weight:397.52
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Orally Active Compound Library
HY-L061
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) AT-56
More
Customer Validation & Images
-
RT-PCR
-
Cell Migration/Invasion Assay
-
In Vivo Efficacy Study
-
IHC
Biological Activity
IC50: 95 μM (L-PGDS); Ki: 75 μM (L-PGDS)[1]
AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD2 in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC50 of about 3 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AT-56 (1-10 mg/kg; p.o.) suppresses the L-PGDS-mediated allergic airway inflammation in mice[1].
AT-56 (10 mg/kg; p.o.) exhibits Cmax (2.15 μg/ml), half-life (1.71 h) and high oral bioavailability (82%)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury[1]
-
Dosage:0, 1, 3, 10, 30 mg/kg
-
Administration:P.o. 1 h before the stab wound injury
-
Result:Inhibited the L-PGDS reaction in the brain.
Decreased the total amount of PGD2 in the brain to 40% with 30 mg/kg AT-56.
-
Animal Model:Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g)[1]
-
Dosage:0, 1, 10 mg/kg
-
Administration:P.o. 1 h before and 24 h after the antigen exposure
-
Result:Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS.
-
Animal Model:Male C57BL/6 mice (7 weeks, 22-26 g)[1]
-
Dosage:10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis)
-
Administration:P.o. and i.v. administration
-
Result:Oral bioavailability (82%); Cmax (2.15 μg/ml); T1/2 (1.71 h, p.o.); T1/2 (2.35 h, i.v.).
Chemical Information
-
CAS No. 162640-98-4
-
Appearance Solid
-
Molecular Weight 397.52
-
Formula C25H27N5
-
Color White to off-white
-
SMILES
N1(CCCCC2=NNN=N2)CC/C(CC1)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Rheumatology (Oxford)
Targeting PTGDS inhibits pro-inflammatory fibroblasts against skin fibrosis in systemic sclerosis. [Abstract]2025 Oct 1;64(10):5551-5561. PMID: 40478772
AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]
The mRNA levels of chemokines in PTGDS-overexpressed (PTGDS-OE) BJ cells with or without AT56 treatment (150 μM) were analysed by RT-PCR.
AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]
Flow chart of the Transwell migration assay upon control BJ cells, PTGDS-OE BJ cells with or without AT56 treatment (150 μM) co-cultured with PBMC or T lymphocytes.
AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]
The SSc skin fibrosis model was established by s.c. injection of BLM (7.5 mg/kg) every other day for 2 weeks. BLM-treated mice were administered daily with either AT56 (10 mg/kg or 30 mg/kg) or vehicle from day 1–14 and were analysed on day 14.
AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]
Representative skin sections with H&E staining, Masson's trichrome staining, and immunohistochemical staining for α-SMA and CD4 in the PBS-treated control mice, and the BLM-induced skin fibrosis mice treated with either vehicle, 10 mg/kg AT56, or 30 mg/kg AT56. Scale bar, 250 μm or 50 μm.
Solvent & Solubility
DMSO : 100 mg/mL (251.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5156 mL | 12.5780 mL | 25.1560 mL | 62.8899 mL |
| 5 mM | 0.5031 mL | 2.5156 mL | 5.0312 mL | 12.5780 mL | |
| 10 mM | 0.2516 mL | 1.2578 mL | 2.5156 mL | 6.2890 mL | |
| 15 mM | 0.1677 mL | 0.8385 mL | 1.6771 mL | 4.1927 mL | |
| 20 mM | 0.1258 mL | 0.6289 mL | 1.2578 mL | 3.1445 mL | |
| 25 mM | 0.1006 mL | 0.5031 mL | 1.0062 mL | 2.5156 mL | |
| 30 mM | 0.0839 mL | 0.4193 mL | 0.8385 mL | 2.0963 mL | |
| 40 mM | 0.0629 mL | 0.3144 mL | 0.6289 mL | 1.5722 mL | |
| 50 mM | 0.0503 mL | 0.2516 mL | 0.5031 mL | 1.2578 mL | |
| 60 mM | 0.0419 mL | 0.2096 mL | 0.4193 mL | 1.0482 mL | |
| 80 mM | 0.0314 mL | 0.1572 mL | 0.3144 mL | 0.7861 mL | |
| 100 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.6289 mL |
AT-56 Related Classifications
HY-13988 Related Classifications
Powered by Bioz